Targeting the angio-proteostasis network: Combining the forces against cancer - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Pharmacology and Therapeutics Année : 2016

Targeting the angio-proteostasis network: Combining the forces against cancer

L. Devisscher
  • Fonction : Auteur
M. Vieri
  • Fonction : Auteur
S.E. Logue
  • Fonction : Auteur
J. Panse
  • Fonction : Auteur
A. Geerts
  • Fonction : Auteur
H. Van Vlierberghe
  • Fonction : Auteur
A.M. Gorman
  • Fonction : Auteur
A. Samali
  • Fonction : Auteur
B. Kharabi Masouleh
  • Fonction : Auteur

Résumé

The VEGF family of pro-angiogenic factors has represented a pillar for targeted cancer therapy for more than a decade. In comparison, the field of protein homeostasis (proteostasis) focusing on the Unfolded Protein Response (UPR), an endoplasmic reticulum (ER) stress-induced signaling cascade, has just recently emerged as an attractive anti-cancer approach. Recent findings suggest that both signaling pathways are incontestably interrelated to ensure cell survival. Herein, we summarize recent findings that demonstrate how these two fundamental aspects of cancer cell survival intersect and provide genetic and pharmacological evidence of the interplay between angiogenic factors such as VEGF-A or PlGF and the individual members of the UPR such as IRE1, PERK and ATF6. We further describe how this interaction does not only affect the cancer cells, but also the surrounding microenvironmental niche that is also involved in tumor progression. Furthermore, by summarizing the recent therapeutic implications of both anti-angiogenic and proteostatic approaches, we emphasize how these novel findings could be used synergistically to improve cancer therapy. © 2016 Elsevier Inc.

Domaines

Cancer
Fichier non déposé

Dates et versions

hal-01417858 , version 1 (16-12-2016)

Identifiants

Citer

L. Devisscher, M. Vieri, S.E. Logue, J. Panse, A. Geerts, et al.. Targeting the angio-proteostasis network: Combining the forces against cancer. Pharmacology and Therapeutics, 2016, 167, pp.1--12. ⟨10.1016/j.pharmthera.2016.07.007⟩. ⟨hal-01417858⟩
28 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More